Clinical trials
Infectious Disease clinical trials
Below are recruiting infectious disease clinical trials, each written for real people, not researchers. We’re tracking 254 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06476132RecruitingPhase 2
Belumosudil for lung transplant patients at risk of chronic rejection
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
Los Angeles, CaliforniaAges 12 years+ - NCT02015013RecruitingPhase 2
Blood cell collection study for immune system disorders
This study collects blood-forming cells from people with low CD4 counts and healthy volunteers to learn how the immune system works. It may help researchers better understand and treat conditions like idiopathic CD4 lymphocytopenia.
Bethesda, MarylandAges 18–65 - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Atlanta, GeorgiaAges 50 years+ - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Birmingham, AlabamaAges 18–75 - NCT05285891RecruitingPhase 4
Stopping ocrelizumab in early relapsing multiple sclerosis
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
New Haven, ConnecticutAges 18–55 - NCT02471378Recruiting
Testing a malaria vaccine in pregnant people with malaria
This study looks at lab tests for malaria vaccine candidates in pregnant women who currently have malaria. It may help researchers understand which vaccine approaches are safest and most promising for pregnancy.
BamakoAges 15–25 - NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Birmingham, AlabamaAges 18 years+ - NCT02140255RecruitingPhase 1/Phase 2
Intensive early HIV treatment in newborns to aim for remission
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
La Jolla, CaliforniaAges Up to 2 days - NCT01132859Recruiting
Study of how immune cells respond in adults
This study looks at how your body’s immune system reacts in different tissues by collecting and storing samples for research. You might be able to join if you’re an adult and can consent, and if you don’t have certain bleeding risks that could make sample collection unsafe.
Bethesda, MarylandAges 18–120 - NCT07569029RecruitingPhase 1
HIV vaccine with treatment break to boost immune response
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
Birmingham, AlabamaAges 18–60 - NCT06203132RecruitingPhase 3
Doravirine vs Dolutegravir for first-time HIV treatment
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
Nova Iguaçu, Rio de JaneiroAges 18 years+ - NCT05403047RecruitingPhase 4
Preventing mom-to-baby hepatitis B with tenofovir
This study tests whether the medicine tenofovir disoproxil can help prevent passing hepatitis B from mother to baby during pregnancy. It is for pregnant women with an active hepatitis B infection who are early in their pregnancy (less than 24 weeks).
TokonbéréAges 16 years+ - NCT02154035Recruiting
Measuring HIV reservoir in Ugandans with suppressed virus
This study in Uganda looks at the HIV 'reservoir' (where the virus hides in the body) in people whose HIV is already well-controlled with medications. It involves blood draws and genetic testing to learn more about the virus.
KalisizoAges 18–49 - NCT04526431Recruiting
Tacrolimus dose study in early kidney transplant patients
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
Grenoble, Auvergne-Rhône-AlpesAges 18 years+ - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Birmingham, AlabamaAges 18 years+ - NCT07111078RecruitingPhase 1
New Flu Vaccine (Stem) with or without Booster
This trial tests a new type of flu vaccine that targets a part of the virus that doesn't change much (the stem). It is given with or without a special booster, and researchers want to see if it provides broader protection against different flu strains.
Bethesda, MarylandAges 18–50 - NCT02257892Recruiting
Study of rare immune system genetic disorders
This study looks for genetic causes of immune problems, such as unusually frequent infections, abnormal allergies, or autoimmune or inflammation conditions. It may help by improving how doctors understand these disorders and by matching families with possible genetic diagnoses.
Bethesda, MarylandAges 3–99 - NCT00339287Recruiting
Healthy adults donate blood to study bacteria-fighting cells
This study looks at how a person’s immune cells interact with bacterial germs. You’d be screened as healthy and may donate blood (and possibly tissue), with samples stored for future research.
Hamilton, MontanaAges 18–120 - NCT06282718Recruiting
Observational study of respiratory infections in primary care
This study tracks how patients with respiratory infections (like bronchitis, sore throats, or COVID-19) are treated in family doctor offices across Europe. The goal is to learn more about these infections and improve care. You may be able to join if you have a cough, sore throat, or other symptoms that suggest a respiratory infection, and you go to a participating clinic.
AntwerpAges Any age - NCT07390955RecruitingPhase 1
Safety study of three anti-HIV antibodies in healthy adults
This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.
Birmingham, AlabamaAges 18–55 - NCT07605520RecruitingEarly Phase 1
COVID-19 Booster Vaccine Study for Previously Vaccinated Adults
This study tests new COVID-19 booster vaccine candidates in healthy adults who previously received mRNA COVID-19 vaccines. Researchers will monitor safety and how well your immune system responds to help develop better COVID-19 protection.
CréteilAges 18–65 - NCT06478017RecruitingPhase 2
Belatacept for heart transplant patients
This study tests whether a drug called belatacept can safely help your body accept a new heart without rejecting it, and may reduce the need for other strong immune-suppressing medicines. If you are getting a heart transplant for the first time and have certain immune markers, this trial may be an option for you.
Los Angeles, CaliforniaAges 18–71 - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT06711575Recruiting
Personalized antibiotics for spinal infections
This trial is studying how to personalize the dose of anti-infection drugs for people with spinal infections. The goal is to find the best treatment for each patient to improve outcomes and reduce side effects.
JinanAges Any age
Hear when a new Infectious Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for infectious disease?
- Yes. Clin2 currently lists 254 recruiting infectious disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a infectious disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a infectious disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.